Sun Pharmaceutical Industries (Sun Pharma) announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi (clascoterone cream 1%).
Sun Pharma Canada, a wholly owned subsidiary of Sun Pharmaceutical Industries Limited has annoucned that PRWINLEVI (clascoterone cream 1% w/w) is now available in Canada. WINLEVI is the first and only androgen receptor inhibitor indicated for the topical treatment of acne vulgaris (acne) in patients 12 years of age and older.
Hyphens Pharma International, Singapore's specialty pharmaceutical and consumer healthcare group, has announced that its subsidiary, Hyphens Pharma Pte. Ltd., has entered into exclusive license and supply agreements with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals N.V. (headquartered in Ireland) for the exclusive rights to develop and commercialise Winlevi® (clascoterone) cream 1% and all future product extension and/or improvement in the treatment of acne in 10 countries across Southeast Asia.
Dublin, Ireland - 26 July 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) announced today that Cassiopea SpA (SIX: SKIN), a company in which it holds 46.56% of the ordinary shares, has signed license and supply agreements with Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, 'Sun Pharma') for WinleviTM (clascoterone cream 1%) for the US and Canada.
Sun Pharmaceutical Industries Ltd has signed license and supply agreement with Cassiopea SpA for Winlevi (clascoterone cream 1%) in the United States and Canada.
Dublin, Ireland - 26 July 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) announced today that Cassiopea SpA (SIX: SKIN), a company in which it holds 46.56% of the ordinary shares, has signed license and supply agreements with Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, 'Sun Pharma') for WinleviTM (clascoterone cream 1%) for the US and Canada.
Sun Pharmaceutical Industries Ltd has signed license and supply agreement with Cassiopea SpA for Winlevi (clascoterone cream 1%) in the United States and Canada.
ALBANY, N.Y.--(BUSINESS WIRE)--Albany Molecular Research, Inc. (AMRI) today announced that it has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.